- Home
- Products
Polivy (Polatuzumab Vedotin-piiqa)
Polivy (Polatuzumab Vedotin-piiqa)
- Medicine Name: Polivy
- Generic Name: Polatuzumab Vedotin-piiq
- Dosage Form & Strength: 30 mg and 140 mg
- Form: Lyophilized powder for injection in single-dose vial
- Manufactured By: Genentech, Inc.
Polivy is a CD79b-directed antibody-drug conjugate used in combination with bendamustine and rituximab to treat adult patients with:
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after two or more lines of systemic therapy.
Recommended Dosage:
- 1.8 mg/kg administered intravenously every 21 days for 6 cycles
- First infusion over 90 minutes, subsequent doses over 30 minutes if well-tolerated
- Premedication with antihistamine and antipyretic is required
Peripheral Neuropathy: Monitor patients from the first cycle; may worsen existing neuropathy
Infusion-Related Reactions: Interrupt infusion and initiate treatment for severe reactions
Myelosuppression: Can cause neutropenia, thrombocytopenia, and anemia; monitor CBCs regularly
Serious Infections: Risk of sepsis, pneumonia, CMV, and herpesvirus infections; prophylaxis recommended
Progressive Multifocal Leukoencephalopathy (PML): Discontinue permanently if diagnose
Tumor Lysis Syndrome: Monitor patients with high tumor burden
Hepatotoxicity: Monitor liver enzymes; pre-existing liver issues increase risk
Fetal Toxicity: Avoid during pregnancy. Use contraception during and for 3 months after last dose
To import Polivy (Polatuzumab Vedotin) to India, the following documents are required:
- Valid prescription from a certified oncologist
- Diagnostic reports confirming DLBCL
- Government-issued photo ID of the patient
- Import permit (if required)
Order Confirmation: Initiated after verification of all documents.
GlobalRareMeds sources Polivy 30 mg / 140 mg from certified international suppliers in the USA, Europe, Canada, and Australia. All medications:
- Are verified under WHO-GDP guidelines
- Are handled with cold-chain protocols
- Are dispatched securely from our licensed fulfillment center in Ambernath, Thane District
Delivery Locations Include:
India (Mumbai, Delhi, Bangalore, Kolkata, Hyderabad, Chennai, Pune, Ahmedabad, and Tier-2 cities) and global regions through legal, named-patient programs.
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Polivy®?
A. Polatuzumab Vedotin-piiq is the generic name.
Q. Who manufactures Polivy?
A. It is manufactured by Genentech, Inc.
Q. Is Polivy FDA approved?
A. Yes, it was approved by the FDA on June 10, 2019.
Q. What condition does Polivy treat?
A. Polivy is used in combination with bendamustine and rituximab to treat relapsed/refractory DLBCL.
Q. How is Polivy administered?
A. By intravenous infusion in a clinical setting, once every 21 days for 6 cycles.
Q. What are the most common side effects?
A. Low blood counts, nerve pain or tingling, fatigue, nausea, diarrhea, decreased appetite, infections, and fever.
Q. What precautions are needed with Polivy?
A. Close monitoring of CBC, liver enzymes, signs of infection, neuropathy, and neurologic changes. Use contraception if of reproductive potential.
Q. What is the price of Polivy 140 mg in India?
A. Pricing varies; contact GlobalRareMeds via WhatsApp (+91-99675 15602) or email for a detailed quote.
Q. Can I buy Polivy online in India?
A. Yes, if unavailable locally, it can be legally procured via GlobalRareMeds.com through our named-patient supply program.
Q. Is Polivy used in first-line therapy?
A. Yes, Polivy has also received approval for first-line treatment of DLBCL in combination with R-CHP regimen based on positive clinical trial outcomes.
Q. Where is Polivy available through GlobalRareMeds?
A. Across India and nearby regions: Mumbai, Pune, Delhi, Hyderabad, Bangalore, Chennai, Ahmedabad, and globally where legal provisions allow.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
